You will be shown the abstract of a medical clinical trial report. Your task is to extract all the findings from this report into a JSON array. Each finding should contain the following five elements:

- Intervention: The medical intervention being tested. This should be a text span copied from the input passage.
- Comparator: The baseline against which the intervention is being evaluated. This should be a text span copied from the input passage. If no comparator is reported, set to `null`.
- Outcome: The medical outcome whose effect is being measured. This should be a text span copied from the input passage.
- Effect: The effect of the intervention on the outcome, relative to the comparator. The effect should be one of the following three values: ("significantly increased", "significantly decreased", "no significant difference").
- Evidence: The evidence for the effect. This should be a text span copied from the input passage.

Please format your output as a JSON array. Each entry in the output should be an array containing the 5 elements listed above, in the following order: [<intervention>, <comparator>, <outcome>, <effect>, <evidence>].

For example, an output with two findings might read:
```
[["aspirin", "placebo", "headache severity", "significantly decreased", "Mean headache severity was significantly decreased in the aspirin group compared to the placebo group (p < 0.05)."], ["aspirin", "placebo", "weight loss", "no significant difference", "We did not observe any difference in weight loss between the group given aspirin relative to the control group"]]
```

There are 3 finding(s) in the abstract below. Please extract them. Output only the JSON array with these 3 findings. Do not include any additional text.

Abstract:
ABSTRACT.BACKGROUND: Established heart failure in thalassaemia major has a poor prognosis and optimal management remains unclear.

ABSTRACT.METHODS: A 1 year prospective study comparing deferoxamine (DFO) monotherapy or when combined with deferiprone (DFP) for patients with left ventricular ejection fraction (LVEF) <56% was conducted by the Thalassemia Clinical Research Network (TCRN). All patients received DFO at 50–60 mg/kg 12–24 hr/day sc or iv 7 times weekly, combined with either DFP 75 at mg/kg/day (combination arm) or placebo (DFO monotherapy arm). The primary endpoint was the change in LVEF by CMR.

ABSTRACT.RESULTS: Improvement in LVEF was significant in both study arms at 6 and 12 months (p = 0.04), normalizing ventricular function in 9/16 evaluable patients. With combination therapy, the LVEF increased from 49.9% to 55.2% (+5.3% p = 0.04; n = 10) at 6 months and to 58.3% at 12 months (+8.4% p = 0.04; n = 7). With DFO monotherapy, the LVEF increased from 52.8% to 55.7% (+2.9% p = 0.04; n = 6) at 6 months and to 56.9% at 12 months (+4.1% p = 0.04; n = 4). The LVEF trend did not reach statistical difference between study arms (p = 0.89). In 2 patients on DFO monotherapy during the study and in 1 patient on combined therapy during follow up, heart failure deteriorated fatally. The study was originally powered for 86 participants to determine a 5% difference in LVEF improvement between treatments. The study was prematurely terminated due to slow recruitment and with the achieved sample size of 20 patients there was 80% power to detect an 8.6% difference in EF, which was not demonstrated. Myocardial T2* improved in both arms (combination +1.9 ± 1.6 ms p = 0.04; and DFO monotherapy +1.9 ± 1.4 ms p = 0.04), but with no significant difference between treatments (p = 0.65). Liver iron (p = 0.03) and ferritin (p < 0.001) both decreased significantly in only the combination group.

ABSTRACT.CONCLUSIONS: Both treatments significantly improved LVEF and myocardial T2*. Although this is the largest and only randomized study in patients with LV decompensation, further prospective evaluation is needed to identify optimal chelation management in these high-risk patients.

Findings:
[["50\u201360\u0026nbsp;mg/kg 12\u201324\u0026nbsp;hr/day sc or iv 7 times weekly, combined with either DFP 75 at mg/kg/day (combination arm)", "placebo (DFO monotherapy arm)", "Improvement in LVEF", "no significant difference", "The LVEF trend did not reach statistical difference between study arms (p\u2009=\u20090.89)."], ["50\u201360\u0026amp;nbsp;mg/kg 12\u201324\u0026amp;nbsp;hr/day sc or iv 7 times weekly, combined with either DFP 75 at mg/kg/day (combination arm)", "placebo (DFO monotherapy arm)", "Myocardial T2", "no significant difference", "Myocardial T2* improved in both arms (combination +1.9\u2009\u00b1\u20091.6\u0026nbsp;ms p\u2009=\u20090.04; and DFO monotherapy +1.9\u2009\u00b1\u20091.4\u0026nbsp;ms p\u2009=\u20090.04), but with no significant difference between treatments (p\u2009=\u20090.65)."], ["50\u201360\u0026amp;nbsp;mg/kg 12\u201324\u0026amp;nbsp;hr/day sc or iv 7 times weekly, combined with either DFP 75 at mg/kg/day (combination arm)", "placebo (DFO monotherapy arm)", "Myocardial T2", "no significant difference", "Myocardial T2* improved in both arms (combination +1.9\u2009\u00b1\u20091.6\u00a0ms p\u2009=\u20090.04; and DFO monotherapy +1.9\u2009\u00b1\u20091.4\u00a0ms p\u2009=\u20090.04), but with no significant difference between treatments (p\u2009=\u20090.65)."]]